HRMY Stock Summary and Trading Ideas (Harmony Biosciences Hldgs | NASDAQ:HRMY)

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Harmony Biosciences Hldgs trades on the NASDAQ stock market under the symbol HRMY.

As of January 15, 2026, HRMY stock price climbed to $36.40 with 154,274 million shares trading.

HRMY has a beta of 1.07, meaning it tends to be more sensitive to market movements. HRMY has a correlation of 0.15 to the broad based SPY ETF.

HRMY has a market cap of $2.10 billion. This is considered a Mid Cap stock.

Last quarter Harmony Biosciences Hldgs reported $239 million in Revenue and $1.08 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.20.

In the last 3 years, HRMY traded as high as $51.30 and as low as $18.61.

The top ETF exchange traded funds that HRMY belongs to (by Net Assets): CALF, SFLO, USVM, FYX, ECML.

HRMY has underperformed the market in the last year with a price return of -0.1% while the SPY ETF gained +20.6%. However, in the short term, HRMY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +35.6% vs +5.2% return in SPY. But in the last 2 weeks, HRMY shares have been beat by the market, returning -2.7% compared to an SPY return of +1.9%.

HRMY support price is $35.18 and resistance is $36.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRMY shares will trade within this expected range on the day.